Xiao‐Yu Yan

Xiao‐Yu Yan

Auto-generated profile, based on publicly available information

Xiao‐Yu Yan

Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
XYXiao‐Yu Yan
Xiao‐Yu Yan
YZYu Zhang
Yu Zhang
JZJuan‐Juan Zhang
Juan‐Juan Zhang
LZLi‐Chao Zhang
Li‐Chao Zhang
YLYa‐Nan Liu
Ya‐Nan Liu
LSLiankun Sun
Liankun Sun
Platinum‐based therapeutic strategies have been widely used in ovarian cancer treatment. However, drug resistance has greatly limited therapeutic efficacy. Recently, tolerance to cisplatin has been attributed to other factors unrelated to DNA . p62 (also known as SQSTM 1) functions as a multifunctional hub participating in tumorigenesis and may be a therapeutic target. Our previous study showed that p62 was overexpressed in drug‐resistant ovarian epithelial carcinoma and its inhibition increased the sensitivity to cisplatin. In this study, we demonstrate that the activity of the NF ‐κB signaling pathway and K63‐linked ubiquitination of RIP 1 was higher in cisplatin‐resistant ovarian ( SKOV 3/ DDP ) cells compared with parental cells. In addition, cisplatin resistance could be reversed by inhibiting the expression of p62 using si RNA . Furthermore, deletion of the ZZ domain of p62 that interacts with RIP 1 in SKOV 3 cells markedly decreased K63‐linked ubiquitination of RIP 1 and inhibited the activation of the NF ‐κB signaling pathway. Moreover, loss of the ZZ domain from p62 led to poor proliferative capacity and high levels of apoptosis in SKOV 3 cells and made them more sensitive to cisplatin treatment. Collectively, we provide evidence that p62 is implicated in the activation of NF ‐κB signaling that is partly dependent on RIP 1. p62 promotes cell proliferation and inhibits apoptosis thus mediating drug resistance in ovarian cancer cells.

10 April 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
YXYa‐Nan Xue
Ya‐Nan Xue
YLYa‐Nan Liu
Ya‐Nan Liu
JSJing Su
Jing Su
JLJiu‐Ling Li
Jiu‐Ling Li
YWYao Wu
Yao Wu
YLYang Li
Yang Li
Metabolic reprogramming is a central hallmark of cancer. Therefore, targeting metabolism may provide an effective strategy for identifying promising drug targets for cancer treatment. In prostate cancer, cells undergo metabolic transformation from zinc‐accumulating, citrate‐producing cells to citrate‐oxidizing malignant cells with lower zinc levels and higher mitochondrial aconitase (ACO2) activity. ACO2 is a Krebs cycle enzyme that converts citrate to isocitrate and is sensitive to reactive oxygen species (ROS)‐mediated damage. In this study, we found that the expression of ACO2 is positively correlated with the malignancy of prostate cancer. Both zinc and p53 can lead to an increase in ROS. ACO2 can be a target for remodeling metabolism by sensing changes in the ROS levels of prostate cancer. Our results indicate that targeting ACO2 through zinc and p53 can change prostate cancer metabolism, and thus provides a potential new therapeutic strategy for prostate cancer.